title: [High-dose carboplatin superselective intraarterial chemotherapy in advanced head and neck cancer].
abstract: Advances in vascular radiology techniques for superselective transfemoral arterial infusion prompted us to evaluate the effects of high-dose rapid regional carboplatin infusion for patients with advanced head and neck squamous cell carcinomas. Twenty untreated patients received three infusions of carboplatin (300-350 mg/m2) every 2 weeks with this method. All the infusions were performed without any complication. Treatment was well tolerated, with moderate (Grade 1-3 WHO) local toxicity (stomatitis, dermatitis and alopecia) and minimal (Grade 1-2 WHO) myelosuppression. The total response index (complete response plus partial response) was 94% for primary tumors and 50% for neck metastases. Neoadjuvant chemotherapy employing superselective rapid infusion of high-dose carboplatin is a feasible, relatively nontoxic, effective technique and may have important applications in multimodality therapy of untreated patients with advanced head and neck cancer.
authors.affiliation: Clinica Otorinolaringoiatrica, Università di Pavia, IRCCS Policlinico S. Matteo.
authors.forename: M
authors.initials: M
authors.lastname: Benazzo
authors.forename: G
authors.initials: G
authors.lastname: Bernardo
authors.forename: F
authors.initials: F
authors.lastname: Corbella
authors.forename: M
authors.initials: M
authors.lastname: Danova
authors.forename: L
authors.initials: L
authors.lastname: Lanza
authors.forename: F
authors.initials: F
authors.lastname: Zappoli
authors.forename: C
authors.initials: C
authors.lastname: Uggetti
authors.forename: E
authors.initials: E
authors.lastname: Mira
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009055:Mouth / Q000473:pathology*; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009305:Nasopharynx / Q000473:pathology*; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009960:Oropharynx / Q000473:pathology*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin